Regencell Bioscience Holdings
Manufacturing · China · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Chinachem Leighton Plaza 29 Leighton Rd ...Phone Number
+852 21550823Website
www.regencellbioscience.comRevenue
-Stock Symbol
RGCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Regencell Bioscience Holdings
Regencell Bioscience Holdings is a bioscience company founded in 2014 that specializes in the research, development, and commercialization of Traditional Chinese Medicine (TCM) treatments. The company focuses on creating remedies for neurocognitive disorders, particularly Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), as well as infectious diseases like COVID-19. Based in China with multiple locations across Asia Pacific, Regencell has conducted research on personalized TCM formulas and is developing standardized liquid-based TCM treatments for varying severities of ADHD and ASD. The company has expanded its reach through joint ventures to provide COVID-19 related treatments in various markets including ASEAN countries, India, Japan, Australia, and New Zealand.Explore more
Regencell Bioscience Holdings Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regencell Bioscience Holdings your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Regencell Bioscience Holdings had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Regencell Bioscience Holdings recently announced quarterly report
Regencell Bioscience Holdings, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Regencell Bioscience Holdings launches new products
Check if Regencell Bioscience Holdings has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Regencell Bioscience Holdings
Funding: Get notified immidiatlly once Regencell Bioscience Holdings has new funding data
Check out if Regencell Bioscience Holdings is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Regencell Bioscience Holdings as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Regencell Bioscience Holdings is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Regencell Bioscience Holdings is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Regencell Bioscience Holdings.
Regencell Bioscience Holdings financials insights
Gather financial insights about Regencell Bioscience Holdings, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$20M
Regencell Bioscience Holdings Tech Stack
A closer look at the technologies used by Regencell Bioscience Holdings
See more technologies
Most Recent Scoops
Funding
Funding
Pain Point
Pain Point, Lawsuits, Legal Affairs, Stake & Stock Ownership, Finance
Initial Public Offering (IPO)
IPO
Initial Public Offering (IPO)
Regencell Bioscience Holdings News & Media
REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Regencell (RGC) To Contact Him Directly To Discuss Their OptionsLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC
Were Regencell's Boilerplate Risk Warnings Adequate? Lawsuit Alleges $14 Billion Company Used Generic Volatility Disclaimers to Mask Specific Market Manipulation Vulnerability Were Regencell's Boilerplate Risk Warnings Adequate? Lawsuit Alleges $14 Billion Company Used Generic Volatility Disclaimers to Mask Specific Market Manipulation VulnerabilityREGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC
NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Regencell (RGC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/23/2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regencell Bioscience Holdings
Sign Up For FreeTo access detailed company insights
Regencell Bioscience Holdings is a bioscience company founded in 2014 that specializes in the research, development, and commercialization of Traditional Chinese Medicine (TCM) treatments. The company focuses on creating remedies for neurocognitive disorders, particularly Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder... Read More
